Safety under the regulatory spotlight — 105 documents in 90 days

48 documents in the last 30 days alone

This concentration of regulatory documents around safety may indicate that agencies are in a tightening phase, or at least that safety oversight is becoming more active and more visible in the near term. Sponsors should consider that this could signal greater scrutiny of signal detection, benefit-risk narratives, post-marketing commitments, and the consistency of safety data across submissions, particularly where emerging adverse event trends or class-wide concerns are involved. Companies with safety programs should be watching for shifts in pharmacovigilance expectations, labeling sensitivity, and any new emphasis on real-world evidence or expedited reporting standards that could reshape how safety packages are assembled and defended.